AU2001238677A1 - Method for preparing anti-mif antibodies - Google Patents
Method for preparing anti-mif antibodiesInfo
- Publication number
- AU2001238677A1 AU2001238677A1 AU2001238677A AU3867701A AU2001238677A1 AU 2001238677 A1 AU2001238677 A1 AU 2001238677A1 AU 2001238677 A AU2001238677 A AU 2001238677A AU 3867701 A AU3867701 A AU 3867701A AU 2001238677 A1 AU2001238677 A1 AU 2001238677A1
- Authority
- AU
- Australia
- Prior art keywords
- preparing anti
- mif antibodies
- mif
- antibodies
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Environmental Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Physics & Mathematics (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Animal Husbandry (AREA)
- Biodiversity & Conservation Biology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18539000P | 2000-02-28 | 2000-02-28 | |
| US60185390 | 2000-02-28 | ||
| US23362500P | 2000-09-18 | 2000-09-18 | |
| US60233625 | 2000-09-18 | ||
| PCT/US2001/005933 WO2001064749A2 (en) | 2000-02-28 | 2001-02-26 | Method for preparing anti-mif antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001238677A1 true AU2001238677A1 (en) | 2001-09-12 |
Family
ID=26881101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001238677A Abandoned AU2001238677A1 (en) | 2000-02-28 | 2001-02-26 | Method for preparing anti-mif antibodies |
Country Status (3)
| Country | Link |
|---|---|
| US (2) | US20030235584A1 (en) |
| AU (1) | AU2001238677A1 (en) |
| WO (1) | WO2001064749A2 (en) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
| DE19957065B4 (en) * | 1999-11-26 | 2005-01-05 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Screening procedure for drugs |
| AU2002231736A1 (en) | 2000-12-22 | 2002-07-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of repulsive guidance molecule (rgm) and its modulators |
| US7361474B2 (en) * | 2003-02-24 | 2008-04-22 | United States Of America As Represented By The Department Of Veterans Affairs | Serum macrophage migration inhibitory factor (MIF) as marker for prostate cancer |
| US20050202010A1 (en) | 2003-08-29 | 2005-09-15 | Giroir Brett P. | Method of treatment and bioassay involving macrophage migration inhibitory factor (MIF) as cardiac-derived myocardial depressant factor |
| JP5198848B2 (en) * | 2004-03-29 | 2013-05-15 | ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ | Treatment of type 1 diabetes using macrophage migration inhibitory factor inhibitor |
| US7555387B2 (en) | 2005-01-28 | 2009-06-30 | Orbitz, L.L.C. | System and method for providing travel related product information on an interactive display having neighborhood categories |
| CA2624562A1 (en) | 2005-09-30 | 2007-04-12 | Abbott Gmbh & Co. Kg | Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use |
| EP2441838A3 (en) * | 2006-01-24 | 2013-07-10 | Domantis Limited | Fusion proteins that contain natural junctions |
| CN100457895C (en) * | 2006-05-24 | 2009-02-04 | 中国科学院生物物理研究所 | Mouse Anti-Human Macrophage Migration Inhibitor Monoclonal Antibody and Its Application |
| CA2706732A1 (en) | 2007-11-30 | 2009-06-11 | Kalobios Pharmaceuticals, Inc. | Antibodies to the pcrv antigen of pseudomonas aeruginosa |
| NZ611117A (en) * | 2008-01-04 | 2014-10-31 | Baxter Int | Anti mif antibodies |
| US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
| US9175075B2 (en) | 2009-12-08 | 2015-11-03 | AbbVie Deutschland GmbH & Co. KG | Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein |
| SI2609118T1 (en) | 2010-08-23 | 2017-05-31 | The Board Of Regents, The University Of Texas System | Anti-ox40 antibodies and methods of using the same |
| US9308255B2 (en) * | 2010-11-24 | 2016-04-12 | Yale University | Methods of administering D-dopachrome tautomerase (D-DT) to treat ischemia-reperfusion injury |
| ES2865068T3 (en) | 2011-01-14 | 2021-10-14 | Univ California | Therapeutic antibodies to ROR-1 protein and methods of using them |
| JP2014526886A (en) * | 2011-07-15 | 2014-10-09 | モルフォシス・アー・ゲー | Antibodies cross-reactive with macrophage migration inhibitory factor (MIF) and D-dopachrome tomerase (D-DT) |
| JP2014530360A (en) * | 2011-10-07 | 2014-11-17 | バクスター・ヘルスケヤー・ソシエテ・アノニムBaxter Healthcare SA | OxMIF as a diagnostic marker |
| EP2753937B1 (en) * | 2011-10-07 | 2018-01-17 | Baxalta GmbH | Characterization of cho-mif gene and protein, and use thereof |
| AU2013211939C1 (en) | 2012-01-27 | 2018-06-07 | AbbVie Deutschland GmbH & Co. KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
| AU2013202693B2 (en) * | 2012-04-16 | 2015-01-22 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics |
| AU2013203957B9 (en) * | 2012-04-16 | 2015-10-15 | Baxalta GmbH | Combination Therapy of Anti-MIF Antibodies and Glucocorticoids |
| WO2013163758A1 (en) | 2012-05-01 | 2013-11-07 | Boyd Shelley Romayne | Methods for treating and diagnosing blinding eye diseases |
| CN105452867A (en) | 2012-07-10 | 2016-03-30 | 巴克斯特保健股份有限公司 | Anti-mif immunohistochemistry |
| AU2013354035A1 (en) | 2012-12-07 | 2015-06-11 | Baxalta GmbH | Anti-MIF antibody cell migration assay |
| RU2656153C1 (en) * | 2013-12-20 | 2018-05-31 | Девелопмент Сентер Фор Байотекнолоджи | Alpha-enolase specific antibodies and methods of uses in cancer therapy |
| US9382331B2 (en) | 2013-12-27 | 2016-07-05 | Development Center For Biotechnology | Alpha-enolase specific antibodies and methods of uses in cancer therapy |
| US10613100B2 (en) | 2014-01-03 | 2020-04-07 | Baxalta Incorporated | Anti-MIF immunohistochemistry |
| WO2016005004A1 (en) | 2014-07-11 | 2016-01-14 | Biontech Rna Pharmaceuticals Gmbh | Stabilization of poly(a) sequence encoding dna sequences |
| WO2016156489A1 (en) | 2015-03-31 | 2016-10-06 | Baxalta GmbH | Dosage regimen for anti-mif antibodies |
| WO2016184886A1 (en) | 2015-05-18 | 2016-11-24 | Baxalta GmbH | Anti-mif antibodies in the treatment of cancers containing mutant tp53 and/or mutant ras |
| TW201736399A (en) | 2015-12-31 | 2017-10-16 | 財團法人生物技術開發中心 | Anti-VEGFR antibody and uses thereof |
| CN109069628A (en) * | 2016-01-14 | 2018-12-21 | Bps生物科学有限公司 | Anti- PD-1 antibody and application thereof |
| JP7437000B2 (en) | 2016-07-01 | 2024-02-22 | パラクライン セラピューティクス アーベー | Methods and compositions for inhibition of PDGF-CC |
| EP3512880A1 (en) * | 2016-09-15 | 2019-07-24 | Ablynx NV | Immunoglobulin single variable domains directed against macrophage migration inhibitory factor |
| KR20200015921A (en) * | 2017-07-03 | 2020-02-13 | 재단법인 생물기술개발중심 | Anti-VEGFR Antibodies and Uses thereof |
| JP2021521173A (en) | 2018-04-11 | 2021-08-26 | オハイオ・ステイト・イノベーション・ファウンデーション | Methods and compositions for sustained release microparticles for intraocular drug delivery |
| WO2019241430A2 (en) * | 2018-06-12 | 2019-12-19 | Angiex, Inc. | Antibody-oligonucleotide conjugates |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0672158B2 (en) * | 1984-05-24 | 1994-09-14 | チバ−ガイギ− アクチエンゲゼルシヤフト | Purified human macrophage migration inhibitory factor |
| US6080407A (en) * | 1993-05-17 | 2000-06-27 | The Picower Institute For Medical Research | Diagnostic assays for MIF |
-
2001
- 2001-02-26 WO PCT/US2001/005933 patent/WO2001064749A2/en not_active Ceased
- 2001-02-26 US US09/791,551 patent/US20030235584A1/en not_active Abandoned
- 2001-02-26 AU AU2001238677A patent/AU2001238677A1/en not_active Abandoned
-
2005
- 2005-06-03 US US11/143,737 patent/US7294753B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US20060191024A1 (en) | 2006-08-24 |
| WO2001064749A3 (en) | 2002-05-02 |
| WO2001064749A2 (en) | 2001-09-07 |
| US20030235584A1 (en) | 2003-12-25 |
| US7294753B2 (en) | 2007-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001238677A1 (en) | Method for preparing anti-mif antibodies | |
| AU2001252588A1 (en) | Method for preparing microsphere | |
| AU2002357049A1 (en) | Methods for preparing 0-desmethylvenlafaxine | |
| AU2001240115A1 (en) | Method for the preparation of tetrahydrobenzothiepines | |
| AU2001295611A1 (en) | Multipressure method for producing ammonia | |
| AU2001239243A1 (en) | Method for producing nanosuspensions | |
| AU2002231135A1 (en) | Method for forming complex ceramic shapes | |
| AU2001291882A1 (en) | Method for producing polyisobutylphenols | |
| AU2001278423A1 (en) | Method for producing aldehydes | |
| AU2406001A (en) | Method for preparing glass-ceramic | |
| AU2002214487A1 (en) | Method for inducing apoptiosis | |
| EP1298117A3 (en) | Method for preparing bromofluorenes | |
| AU2001231920A1 (en) | Method for preparing alpha-halogenated ketones | |
| AU2001268981A1 (en) | Method for producing 2-chloro-5-chloromethyl-1,3-thiazole | |
| HUP0301893A3 (en) | Method for producing 2-chloro-5-chloromethyl-1,3-thiazole | |
| AU2002222604A1 (en) | Process for preparing substance GM-95 | |
| AU2002231187A1 (en) | Method for synthesizing diamond | |
| AU2002220757A1 (en) | Method for obtaining azaerythromycin | |
| AU2002212224A1 (en) | Method for producing delta1-pyrrolines | |
| AU4663601A (en) | Method for preparing 9-deoxo-8a-aza-(8a-alkyl)-8a-homoerythromycin derivativesfrom 9-deoxo-9(z)-hydroxyiminoerythromycin | |
| AU2001262147A1 (en) | Method for producing 4-bromo- and 4-chloro-2-nitro-1-trifluoromethoxybenzene | |
| AU2002241271A1 (en) | Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate | |
| AU2001272448A1 (en) | Method for producing dna-arrays | |
| HUP0401401A3 (en) | Method for preparing 7-quinolinyl-3,5-dihydroxyhept-6-enoate | |
| AU2001295042A1 (en) | Anti-stilbene antibodies |